Patients candidated for coronary angiography by contrast media. Ischemic Heart Diseases
Conditions
Interventions
Intervention 1: Intervention: patients in this group based on randomization will receive Dixopaque of Shahid Ghazi with a single dose of 320 mg intravenously. Intervention 2: Control:patients in this
Diagnosis
Intervention: patients in this group based on randomization will receive Dixopaque of Shahid Ghazi with a single dose of 320 mg intravenously.
Control:patients in this group based of randomization will receive Visipaque with a single dose of 320 mg intravenously.
Sponsors
Shahid Ghazi Pharmaceutical Company
Eligibility
Sex/Gender
All
Age
45 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients aged between 45 to 65 years old; referred subjects for coronary angiography by contrast media; provided signed and dated informed consent subjects. Exclusion criteria: patients with contrast administration in the past 7 days; subjects have known contra-indication and allergy to contrast administration; renal insufficiency as defined by GFR < 50; lactation; pregnancy; bronchial asthma; clinical unstable condition (hemodynamic, respiratory, neurologic); emergency cases; hyperthyroidism; end-stage patients.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Image Quality. Timepoint: After coronary angiograghy. Method of measurement: Scoring by investigator from 1 to 10. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events of contrast media. Timepoint: During injection and 24 after injection. Method of measurement: Interview, Physical exam, Lab test.;Renal toxicity. Timepoint: Before and 24 hours after injection. Method of measurement: Serum creatinine examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Ramin Heshmat
Chronic Diseases Research Center
Outcome results
None listed